Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 20/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 20/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16523110 | 0.91 | FGFR3 (0.84) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14905203 | 0.91 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16523111 | 0.89 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14905241 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14901182 | 0.88 | FGFR3 (0.78) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14906680 | 0.88 | FGFR3 (0.78) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14905516 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20808376 | 0.86 | FGFR1 (0.91) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14905455 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL18768878 | 0.86 | FGFR1 (0.80) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR1 2337/4885FGFR2 2426/4885FGFR4 1858/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR1 2337/4885FGFR2 2426/4885FGFR4 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.